5T4抗体;5T4 Antibody—艾普蒂 新品

+ +

•  

   

     Western blot analysis of 5T4 expression in Caco-2 cell lysates.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human uters cancer, using 5T4 Antibody.    

  
  

The 5T4 antibody targets the 5T4 oncofetal antigen, also known as trophoblast glycoprotein (TPBG), a cell surface glycoprotein overexpressed in various cancers but minimally expressed in healthy adult tissues. Initially identified in placental trophoblast cells during embryogenesis, 5T4 is re-expressed in malignancies such as colorectal, ovarian, gastric, and non-small cell lung cancers. Its role in tumor progression involves promoting epithelial-mesenchymal transition (EMT), metastasis, and immune evasion, making it a promising therapeutic target. Structurally, 5T4 contains leucine-rich repeats and N-glycosylation sites, facilitating interactions with extracellular matrix components and signaling pathways like Wnt/β-catenin.

Antibodies against 5T4. including monoclonal antibodies (e.g., A5B7) and antibody-drug conjugates (ADCs), aim to block tumor growth or deliver cytotoxic payloads directly to cancer cells. Preclinical studies highlight their potential to inhibit metastasis and enhance chemotherapy sensitivity. Additionally, 5T4-targeted CAR-T cell therapies and vaccines are under exploration. Despite promising early results, challenges remain, including tumor heterogeneity in 5T4 expression and optimizing therapeutic efficacy while minimizing off-target effects. Ongoing research focuses on combination strategies with immune checkpoint inhibitors or radiotherapy to amplify anti-tumor responses. Overall, 5T4 antibodies represent a versatile tool in oncology, bridging targeted therapy and immunotherapy paradigms.